Serum antimullerian hormone and allcause mortali

Authors: Rehan Qayyum Sana Akbar

Publish Date: 2016/08/08

Volume: 54, Issue: 1, Pages: 225-231

PDF Link

Abstract

Several studies have examined an association of antimullerian hormone to various risk factors for mortality however to the best of our knowledge no study has reported a direct relationship between antimullerian hormone and allcause mortality Therefore we examined the relationship between baseline antimullerian hormone levels and subsequent allcause mortality in men during median followup of 94 range = 0−13 years We used the continuous National Health and Nutrition Examination Surveys from 1999–2004 combined with National Death Index for vital status information through December 2011 Cox proportional hazard models were fit to estimate hazard ratios for allcause mortality Models were adjusted for age ethnic background body mass index hypertension diabetes smoking status creactive protein total cholesterol estimated glomerular filtration rate serum estradiol testosterone sex hormone binding globulin and androstenedione Of the 989 men 30  were older than 65 years 51  were Caucasians 33  had hypertension 27  were active smokers and 11  had diabetes Mean serum antimullerian hormone level of the population was 72 63 ng/mL During the 8943 personyears of followup 164 17  men died In unadjusted analysis each unit increase in serum antimullerian hormone level was associated with a 13  lower risk of death HR = 087 95 CI = 083–092 In multivariable models the inverse association between serum antimullerian hormone levels and mortality remained significant HR = 094 95 CI = 090–098 and was independent of confounding variables Similarly individuals in the highest quartile had significantly lower risk of death as compared to individuals in the lowest quartile unadjusted HR = 013 95 CI = 007–025 adjusted HR = 036 95 CI = 016–081 We found an independent and inverse association between serum antimullerian hormone levels and allcause mortality in men The mechanism underlying this association is unknown Further studies are needed to validate our findings in men and to examine this association in womenRehan Qayyum was on the speaking panel of the Sunovion Pharmaceuticals for Brovana® last year and is on the National COPD Health Outcomes Research Panel for Sunovion Pharmaceuticals for this year Both of these relationships are in a completely different medical field and did not affect this study in any shape or form These relationships are being declared for complete transparency The remaining authors declare that they have no conflict of interest

Keywords: